Abstract
Anti-platelet aggregation of copper aspirinate, a copper complex of aspirin, has been studied in vitro and in vivo. The result shows that copper aspirinate is much more effective than aspirin against AA-, ADP- and PAF-induced platelet aggregation. Its mechanism is related to the inhibition of platelet cyclooxygenase and release of active substances from platelets, and to the promotion of PGI2 level in plasma.
This is a preview of subscription content, log in via an institution to check access.
References
Sorensen JRJ.Copper Complexes offer a physiological approach to treatment of chronic leases. Prog Med Chem. 1989;26:437–568
Sorensen JRJ. Preliminary chronic toxicity study of copper aspirinate. Inorg Chim Acta. 1984;91:L31–4.
Sorensen JRJ. Copper chelates as possible active forms of the antiarthritic agents. J Med Chem. 1976;19(1):135–48.
Born GVR Aggregation of blood platelets by adenosime diphosphate and its reversal. Nature. 1962;194:927–9.
Wang Z, Huang RS. Radioimmunoassay for thromboxane B2.Acta Acad Med Sin. 1986;8:139–42.
Shi YQ, Li ZH. Radioimmunoassay for thromboxane B2. Acta Acad Med Sin. 1986;8310–12
Bose KS, Patel CC. Structure of copper complexes of carboxylates. Ind J Chem. 1970;8:840–2.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weiping, L., Yang, Y.K., Xiong, H.Z. et al. Coordination of copper with aspirin enhances its anti-platelet aggregation activity. Inflammopharmacol 5, 133–138 (1997). https://doi.org/10.1007/s10787-997-0022-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10787-997-0022-9